Research programme: molecular glue degrader therapeutics - Monte Rosa Therapeutics/Roche
Latest Information Update: 16 Jan 2024
At a glance
- Originator Monte Rosa Therapeutics
- Developer Monte Rosa Therapeutics; Roche; Yeda Research and Development Company Ltd
- Class Antineoplastics; Small molecules
- Mechanism of Action Protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer; Neurological disorders
Most Recent Events
- 17 Oct 2023 Molecular glue degrader therapeutics licensed to Roche
- 17 Oct 2023 Early research in Cancer in USA (unspecified route) (Monte Rosa Therapeutics pipeline, December 2023)
- 17 Oct 2023 Early research in Neurological disorders in USA (unspecified route) (Monte Rosa Therapeutics pipeline, December 2023)